Across TCGA pan-cancer cohorts, BTN3A2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of BTN3A2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where BTN3A2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types BTN3A2 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

CCRCC, LUAD, and LSCC are the cancer types where BTN3A2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BTN3A2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	All	+1.430	<.001	12	view →
LUAD	Female	All	−0.650	<.001	9	view →
LSCC	Male	II,III,IV	−0.606	<.001	7	view →
HNSC	Male	III,IV	−0.436	.011	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: BTN3A2 RNA expression & survival · all BTN3A2 data types